<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236273</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM3960</org_study_id>
    <nct_id>NCT02236273</nct_id>
  </id_info>
  <brief_title>Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents</brief_title>
  <official_title>Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <brief_summary>
    <textblock>
      Emerging communication technologies, such as text messaging offer low-cost, scalable
      opportunities to improve health literacy and promote healthy behaviors, such as vaccination.
      While the investigators reported the success of text message vaccine reminders, effects were
      limited by their untailored approach. The trans-theoretical model of behavior change
      supports tailoring interventions to an individual's stage of decision-making. Human
      papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can
      lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is
      90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV
      vaccine completion rates. Limited health literacy regarding the vaccine can affect series
      completion. The investigators will compare the effects of enhancing text message vaccination
      reminders with interactive, vaccine health literacy-promoting information tailored to
      vaccine decision making-stage on HPV vaccine series completion. The effects of these
      messages represent a new paradigm in interactive health communications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV vaccine series completion</measure>
    <time_frame>12 months</time_frame>
    <description>receipt of 3 doses of HPV vaccine by 12 months after initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time between 1st and 2nd dose</measure>
    <time_frame>2 months</time_frame>
    <description>Time elapsed in weeks between first and second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between 1st and 3rd dose</measure>
    <time_frame>6 months</time_frame>
    <description>Time elapsed (in months) between 1st and 3rd dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">956</enrollment>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Conventional Text Message</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional text message reminder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced reminders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enhanced text message reminders</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional text message reminder</intervention_name>
    <description>Receipt of conventional text message notifying when due for next dose</description>
    <arm_group_label>Conventional Text Message</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced text message reminders</intervention_name>
    <description>Receipt of enhanced text messages notifying when due for next dose coupled with educational information</description>
    <arm_group_label>Enhanced reminders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parenting adult of adolescent age 11-17 years

          -  Adolescent received 1st dose of HPV at a study site within the last 2 weeks.

          -  Eligible parent's cell phone has text message capability

        Exclusion Criteria:

          -  Language other than English or Spanish only

          -  Parent already in the study

          -  Intends to move away from the New York City area in &lt;12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa S Stockwell, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Stockwell, MD MPH</last_name>
    <phone>212-342-5732</phone>
    <email>mss2112@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Stockwell, MD MPH</last_name>
      <phone>212-342-5732</phone>
      <email>mss2112@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa S Stockwell, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Catallozzi, MD, MSCE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>September 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Melissa Stockwell</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics and Population and Family Health</investigator_title>
  </responsible_party>
  <keyword>Human papillomavirus</keyword>
  <keyword>vaccination</keyword>
  <keyword>text message</keyword>
  <keyword>reminder</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
